Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | GRM5 | P41594 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8022200 | 0.80 | GFER (0.51) | GFERGRM5 | |
| SCHEMBL14907878 | 0.80 | GFER (0.51) | GFERGRM5 | |
| SCHEMBL1751529 | 0.80 | GFER (0.50) | GFERGRM5CA12CA1CA2 | |
| SCHEMBL8022201 | 0.79 | GRM5 (0.44) | GFERGRM5 | |
| SCHEMBL2636049 | 0.79 | GFER (0.55) | GFERGRM5CA12CA1CA2 | |
| SCHEMBL666992 | 0.79 | APP (0.49) | GFERGRM5 | |
| SCHEMBL4554708 | 0.78 | NPSR1 (0.55) | GFERGRM5 | |
| SCHEMBL29961896 | 0.78 | GFER (0.48) | GFERGRM5CA12CA1CA2 | |
| SCHEMBL28501126 | 0.78 | GFER (0.48) | GFERGRM5CA12CA1CA2 | |
| SCHEMBL6563747 | 0.77 | CA12 (0.51) | GFERGRM5CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2539340-B1 | PYRAZOLOPYRIDAZINE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2014-08-27 | — | — | EP | disclosed |
| EP-2539340-A1 | PYRAZOLOPYRIDAZINE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2013-01-02 | — | — | EP | disclosed |
| US-8324212-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120046294-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-23 | — | — | US | disclosed |
| WO-2011106340-A1 | PYRAZOLOPYRIDAZINE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-01 | — | — | WO | disclosed |
| EP-0944581-A4 | PROCESS OF PREPARING SUBSTITUTED ACRYLAMIDES | LILLY CO ELI (US) | 2004-09-08 | — | — | EP | disclosed |
| US-6069247-A | REACTING AN ACETYLENECARBOXY AMIDE AND AN ARYL OR HETEROCYCLYL HALIDE OR A GROUP ENHANCING THE ELECTROPHILICITY OF THE ATOM TO WHICH IT IS ATTACHED FOR DISPLACEMENT; USING A PALLADIUM COMPOUND CATALYST, A BASE AND AN ACID | ELI LILLY AND COMPANY (US) | 2000-05-30 | — | — | US | disclosed |
| EP-0944581-A1 | PROCESS OF PREPARING SUBSTITUTED ACRYLAMIDES | ELI LILLY AND COMPANY (US) | 1999-09-29 | — | — | EP | disclosed |
| US-5917038-A | REACTING PROPIOLAMIDE WITH ACTIVATED AROMATIC RING IN THE PRESENCE OF A PALLADIUM CATALYST | ELI LILLY AND COMPANY (US) | 1999-06-29 | — | — | US | disclosed |
| WO-1998022429-A1 | PROCESS OF PREPARING SUBSTITUTED ACRYLAMIDES | ELI LILLY AND COMPANY (US) | 1998-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046294-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | GFER 2293/4885GRM5 4578/4885CA12 1392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.